AstraZeneca’s PR department doesn’t stop, neither on Sunday–this afternoon, it issued a release announcing that cancer drug Lynparza (PARP inhibitor) has shown efficacy on women with newly-diagnosed ovarian carcinoma. Specifically, scientists from the Britain-based group have introduced at the European Society for Medical Oncology congress, currently held in Munich, results from the Solo-1 clinical trial, conducted in women with BRCA-mutated ovarian cancer. The results show that Lynparza reduces cancer progression in 60% of cases, whereas placebo blocks it in 27%. According to analysts, should Lynparza be approved as a first-line treatment, it would contribute as little as $500m to the group’s revenues, since the genetic mutation of the cancer on which it has been tested is fairly rare. Lynparza, which has been developed in partnership with Merck & Co, has already been approved for other indications and it is expected to generate $4bn pa before 2023. Importantly, Lynparza some months ago was granted “orphan drug” designation for the treatment of pancreas cancer.